VRTX
NasdaqVERTEX PHARMACEUTICALS INC / MA
Health Care, Biotechnology
$496.07
close 7 Aug 2026
+32.48%
52-week change
$125.68B
market cap
$362.50
$533.67
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | |||||||||||||||||||
| Revenue | $12.59B | $12.00B | $11.02B | $9.87B | $8.93B | $7.57B | $6.21B | $4.16B | $3.05B | $2.49B | $1.70B | $1.03B | $580.42M | $1.21B | $1.53B | $1.41B | $143.37M | $101.89M | $175.50M |
| Cost of revenue | $1.76B | $1.65B | $1.53B | $1.26B | $1.08B | $904.20M | $736.30M | $547.80M | $409.54M | $275.12M | $210.46M | $117.15M | $39.73M | $88.98M | $236.74M | $63.63M | $0.00 | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| R&D | $3.91B | $3.91B | $3.63B | $3.16B | $2.54B | $1.94B | $1.64B | $1.75B | $1.42B | $1.32B | $1.05B | $995.92M | $855.51M | $882.10M | $765.91M | $707.71M | $637.42M | $550.27M | $516.91M |
| SG&A | $2.01B | $1.75B | $1.46B | $1.14B | $944.70M | $840.10M | $770.50M | $658.50M | $557.62M | $496.08M | $432.83M | $376.58M | $305.41M | $356.19M | $432.68M | $400.72M | $187.80M | $130.19M | $101.29M |
| Operating income | $4.78B | $4.17B | -$232.90M | $3.83B | $4.31B | $2.78B | $2.86B | $1.20B | $635.15M | $123.24M | $9.94M | -$466.88M | -$692.41M | -$610.01M | $46.73M | $113.82M | -$696.08M | -$614.01M | -$462.71M |
| Interest expense | — | $13.30M | $30.60M | $44.10M | $54.80M | $47.40M | $58.15M | $58.50M | $72.47M | $69.30M | — | — | — | — | $16.65M | $38.45M | $19.28M | $13.19M | $13.47M |
| Tax expense | $869.30M | $690.00M | $784.10M | $760.20M | $910.40M | $388.30M | $405.20M | $218.10M | -$1.49B | -$107.32M | $16.67M | $30.38M | $6.96M | -$122.42M | -$275.00K | $19.27M | $0.00 | — | — |
| Net income | $4.41B | $3.95B | -$535.60M | $3.62B | $3.32B | $2.34B | $2.71B | $1.18B | $2.10B | $263.48M | -$112.05M | -$556.33M | -$738.56M | -$445.03M | -$107.03M | $29.57M | -$754.63M | -$642.18M | -$459.85M |
| Diluted EPS | $17.17 | $15.32 | -$2.08 | $13.89 | $12.82 | $9.01 | $10.29 | $4.51 | $8.09 | $1.04 | -$0.4600 | -$2.31 | -$3.14 | -$1.98 | -$0.5000 | $0.1400 | -$3.77 | -$3.71 | -$3.27 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | 37.95% | 34.77% | -2.11% | 38.83% | 48.23% | 36.73% | 46.03% | 28.77% | 20.84% | 4.95% | 0.58% | -45.23% | -119.30% | -50.33% | 3.06% | 8.07% | -485.51% | -602.63% | -263.65% |
| Net margin | 35.00% | 32.94% | -4.86% | 36.68% | 37.20% | 30.92% | 43.70% | 28.27% | 68.80% | 10.59% | -6.58% | -53.89% | -127.25% | -36.72% | -7.01% | 2.10% | -526.35% | -630.27% | -262.02% |
filed 4 Aug 2026